"Supportive care" may hold less stigma than "palliative care"
the ONA take:
Hematologic specialists were less likely to refer patients early in the disease trajectory to palliative care and were conducive to referral with the service name supportive care instead of palliative care, a new study published online ahead of print in the journal The Oncologist has shown.
Because palliative care referrals are often delayed for patients with hematologic malignancies, researchers sought to examine the differences in attitudes and beliefs toward palliative care referral between hematologic and solid tumor specialists and how their perception was altered with the service name supportive care instead of palliative care.
For the study, researchers surveyed 120 hematologic and 120 solid tumor oncology specialists at University of Texas MD Anderson Cancer Center in Houston, Texas.
Results showed that hematologic specialists were less likely than solid tumor specialists to report that they would refer symptomatic patients with newly diagnosed cancer to palliative care.
Researchers also found that a significantly greater proportion of oncology specialists reported that they would refer a patient with newly diagnosed cancer to supportive care than palliative care, even though they both provide the same service.
“These findings suggest that rebranding might help to overcome the stigma associated with palliative care and improve patient access to palliative care services,” the authors conclude.
Hematologic specialists were less likely to refer patients early in the disease trajectory to palliative care.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|